CAMP4 Therapeutics Corporation Common Stock (CAMP) Stock
Key stats
- Market cap
- $263.57M
- Price / Earnings ratio
- -2.2x
- EPS (TTM)
- -$2.14
- Volume
- Loading
- 52-week high
- $7.75
- 52-week low
- $2.90
Source: third-party data provider, as of November 13, 2026
Compare with CAMP
Recent news

CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
CAMP

CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
CAMP

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
CAMP

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
CAMP
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 57.54
- MACD 12/26/9
- 0.14
- EMA 9 of MACD
- 0.03
- MACD histogram
- 0.10
- SMA 50
- $3.87
- Price above SMA 50
- EMA 50
- $3.87
- Price above EMA 50
- SMA 200
- $4.20
- Price below SMA 200
- EMA 200
- $4.23
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
CAMP

CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
CAMP

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
CAMP

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
CAMP

CAMP4 advances rare disease treatment for SYNGAP1 into human trials
CAMP4 advances rare disease treatment for SYNGAP1 into human trials
CAMP

New Strong Sell Stocks for July 16th
New Strong Sell Stocks for July 16th
CAMP

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP

Top 3 Tech Stocks Which Could Rescue Your Portfolio This Month - Digital Turbine (NASDAQ:APPS), CalAmp (NASDAQ:CAMP)
Top 3 Tech Stocks Which Could Rescue Your Portfolio This Month - Digital Turbine (NASDAQ:APPS), CalAmp (NASDAQ:CAMP)
CAMP

Best Penny Stocks Today? 3 That Funds & Insiders Are Buying Now
Best Penny Stocks Today? 3 That Funds & Insiders Are Buying Now
CAMP
News tone: automated (AI) classification of the article's content, not a price prediction.
About CAMP4 Therapeutics Corporation Common Stock
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joshua Mandel-Brehm | CEO, President & Director | 1983 |
| Dr. Leonard I. Zon M.D. | Founder & Chairman of Scientific Advisory Board | — |
| Ms. Kelly Gold | Chief Financial Officer | 1977 |
| Dr. Richard A. Young Ph.D. | Founder & Independent Director | 1954 |
| Dr. Yuri Maricich M.B.A., M.D. | Chief Medical Officer | 1981 |
| Mr. Caleb Moore | Chief Business Operations Officer | — |
| Dr. Daniel Tardiff Ph.D. | Chief Scientific Officer | 1980 |
| Ms. Michelle Gates | Senior VP & Chief People Officer | — |
| Ms. Alla Sigova Ph.D. | Senior Vice President of Platform | — |
| Dr. Satya Kuchimanchi Ph.D. | Senior Vice President of Technical Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 57.54
- MACD 12/26/9
- 0.14
- EMA 9 of MACD
- 0.03
- MACD histogram
- 0.10
- SMA 50
- $3.87
- Price above SMA 50
- EMA 50
- $3.87
- Price above EMA 50
- SMA 200
- $4.20
- Price below SMA 200
- EMA 200
- $4.23
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $6.00
- Average
- $10.80
- High
- $15.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.1 | -22.4 | ||||||||||
| 2022 | -16.5 | +17.9 | +5.9 | -23.6 | +26.3 | -41.8 | +10.8 | +25.9 | -31.3 | -3.3 | -5.5 | +25.1 |
| 2023 | +3.1 | -9.5 | -17.5 | -27.2 | -28.7 | -40.4 | -12.3 | -34.5 | -35.6 | -42.1 | +38.2 | -19.9 |
| 2024 | -46.1 | -18.4 | +20.0 | -4.3 | -19.1 | -35.6 | ||||||
| 2026 | -29.8 | -6.5 | +8.4 | +8.2 | -20.5 | -5.9 | +6.6 | +3.1 | +11.1 |



